Orphan Drugs for Rare Diseases Summit

2nd Precision Medicine Summit with focus on “Orphan Drugs for Rare Diseases“, scheduled for March 22-23, 2018 in Berlin, Germany.

This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development.

The summit will shed light on current challenges, best practices and the inside view of the future of Orphan Drugs for Rare Diseases.

We will discuss key findings, including critical insights, as well as recommendations for driving efficient strategies in Orphan Drugs for Rare Diseases landscape.

We look forward to welcoming you in Berlin upcoming March.

Key Practical Learning Points of the Summit:

  • Cutting-edge science and tech to enhance rare diseases research, diagnosis and therapeutics
  • Novel drug modalities, assays & models, therapeutic strategies
  • Employee wellbeing & health in relation to office design
  • Emerging approaches for effective, fast, affordable and successful orphan drugs development
  • Insights into regulatory, pricing, reimbursement, commercialization, market access for rare disorders drugs

Who Should Attend:

Chief Executives, Directors, Vice Presidents, Heads, Leaders and Managers specialising in:

  • Drug Discovery & Development
  • Personalized Medicine
  • Translational Medicine
  • Experimental Medicine
  • Innovative Medicine
  • Stratified Medicine
  • Regenerative Medicine
  • Cell / Molecular Biology
  • Molecular Diagnostics
  • Diagnostic Development
  • Cell / Gene Therapy
  • Targeted Therapy
  • Rare & ultra-rare Diseases
  • Genetic Diseases
  • Metabolic & Gastrointestinal (GI) disorders
  • Endocrinology
  • Cardiovascular, pulmonological disorders
  • Cancer / Oncology
  • Neurology, mental health, neuromuscular and musculoskeletal disorder
  • Dermatology, ophthalmology, urology and nephrology Immunology
  • Haematology
  • Immunology
  • Non-Hodgkin Lymphoma
  • Acute Myeloid Leukemia
  • Cystic Fibrosis
  • Glioma
  • Pancreatic Cancer
  • Ovarian Cancer
  • Multiple Myeloma
  • Duchenne Muscular Dystrophy
  • Graft vs Host Disease
  • Renal Cell Carcinoma
  • Clinical Research / Trials / Development
  • Market Access
  • Pricing & Reimbursement
  • Alliance Management
  • Patient Advocacy
  • n-Licensing/Out-Licensing
  • Regulatory & Medical Affairs
  • Commercial Development
  • Health Economics/Outcomes Research (HEOR)
  • Orphan Foundations/Associations
  • Bioinformatics
  • Big Data
  • Digital Health
Speakers